This week's roundup of Houston innovators includes Chris George of Octopus EV, James Allison of MD Anderson, and Paul Wotton of RBL LLC. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a biotech leader, a Nobel laureate, and EV innovator.

Chris George, United States co-lead at Octopus Electric Vehicles

Chris George, United States co-lead at Octopus Electric Vehicles, joins the Houston Innovators Podcast. Photo courtesy of Octopus

Switching from a gas-powered car to an electric one can be a big change, but a Houston-based company has made things a lot easier for its customers.

Octopus Electric Vehicles US, a spinout of United Kingdom-based retail energy provider Octopus Energy, matches its users with their perfect EV lease and sets them up with smart electricity technology for at-home charging.

"We do a couple of really unique things that are not only first of its kind but really innovative," Octopus EV's US Co-Lead Chris George says on the Houston Innovators Podcast, pointing out specifically Octopus Energy's Intelligent Octopus, a smart feature for customers that automates energy usage to lower cost.

"We launched an Intelligent Octopus for EVs service. Instead of operating in a very narrow window — overnight — it operates dynamically," he continues. Read more.

James P. Allison, director of the James P. Allison Institute

MD Anderson's lab led by Nobel laureate James Allison has secured a $5 million donation. Photo courtesy of MD Anderson Cancer Center

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center scored a $5 million gift at its second annual symposium.

On behalf of Mayor John Whitmire, Oct. 10, 2024 was named “James P. Allison Institute Day,” and it was also the day that the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park greeted 900 attendees for the scientific symposium, entitled “Immunotherapy in Space and Time: The Tumor Microenvironment.”

“Spatial biology is a rapidly expanding field that offers tremendous new insights into immunobiology that were not possible just a few short years ago. Understanding how immune cells interact with their neighbors and with tumor cells in space and time will enable us to bring forward new strategies to improve immunotherapy outcomes,” says James P. Allison. “We are proud to host this annual symposium to advance the field, and we are extremely grateful for the support of the Wintermann Foundation to make new breakthroughs possible.” Read more.

Paul Wotton, managing partner of RBL LLC

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is Rice University's new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems." Continue reading.

From advice to observations, these five quotes overheard at SXSW proves Houston had some great spokespeople at the 2019 SXSW Interactive festival. Photos courtesy

Overheard: 5 powerful quotes from Houstonians speaking at SXSW

Eavesdropping in Austin

Houston had no shortage of representatives at the 2019 SXSW Interactive festival, which took place March 8 to 12 in Austin. Several sat on panels, lead mixers, or even starred in a movie for the film track of the conference.

I had the pleasure of sitting in on a great deal of these events featuring the best and the brightest of Houston's innovation stars, but I realize most did not. To catch you up and rid you of your fear of missing out, check out these five overheard quotes from the fest.

"I think it's so important to find your focus and know what to say no to, because you can't do it all. Elizabeth [Gore] and I have a monthly 'meeting of no' where we literally check off things off our plate that we need to stop doing because we just don't have enough time. It's probably one of our most valuable hours."

Carolyn Rodz, co-founded Alice with Elizabeth Gore. Alice co-hosted a series of panels at the Bumble Hive. She was asked, during the investment-focused panel, about focusing on B-to-B vs. B-to-C as a startup. Alice and Bumble just recently announced a partnership.

"We're trying to awaken the sleeping giant — a really huge city with lots of money, trying to infiltrate and activate huge family offices and rally people behind the goal of building a vibrant startup community. We've got a long way to go in terms of attracting VC talent — we're still behind Austin and Dallas."

Lawson Gow, founder and CEO of The Cannon, at the Austinpreneur podcast recording of "The Texas Startup Manifesto" episode. He was asked about what he's been trying to accomplish at The Cannon. Gow is the son of InnovationMap's parent company's CEO.

"We've got all the basic tools, and we know what the main issues are. There's still a lot to do, but we need to be smart and do fact-based and mechanism-based combinations."

James Allison, chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center. At his panel, "Making the Fight Against Cancer Even More Personal," he was asked about the current status of immunotherapy research.

“Have very specific questions. I hate the ‘can I pick your brain’ request. If you want advice on something, ask me that specifically. And, show up at everything. … It’s not about what network you have, but how many networks you can get into.”

Grace Rodriguez, CEO and executive director of Impact Hub Houston. On the "Equitable Growth Ecosystems for Entrepreneurs" panel, she was asked about how an entrepreneur might try to grow their network and mentorship.

"Houston is an incredibly industrial town. We have more Fortune 500 companies here than anywhere other than New York — most of them in the world of the dirty and dangerous. We don't have a lot of scooter companies."

Gabriella Rowe, CEO of Station Houston. She was asked while on her panel, "Startup Funding: From Apprenticeships to Professions," about bootstrapping as a startup. Read more about this discussion here.

Jim Allison, immunotherapy researcher at MD Anderson and Nobel Prize recipient, is the subject of a new film that premiered at SXSW. Photo courtesy of MD Anderson Cancer Center

Film about Nobel Prize-winning Houston scientist premieres at SXSW

Now showing

For most of his career, James Allison has been a cancer research wildcatter fighting an oftentimes lonely battle for the advancement of immunotherapy. The medical community has historically been skeptical of the science, but nonetheless Allison dedicated his life to developing a better treatment to the disease that has claimed so many lives — including his mother's.

Last year, Allison, the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson, won the 2018 Nobel Prize in medicine, and Breakthrough, a film about Allison's progression from early researcher to Nobel Prize recipient, premiered on March 9 at the 2019 SXSW Interactive festival.

But despite the Nobel Prize and the new film both validating the science to the public, Allison says there's a lot more work to be done in immunotherapy. Allison, his colleague, Padmanee Sharma, and the filmmaker for Breakthrough, Bill Haney, hosted a discussion at SXSW about the future of immunotherapy.

"It's a time of considerable optimism — and we're just at the beginning," says Allison.

The film focuses on the man behind the science — a 70-year-old, harmonica-playing researcher from small-town Alice, Texas. It's both an ode to Allison's career and a thought-provoking take on all the work left to be done in the industry.

Immunotherapy is the process of targeting one's immune system's T-cells, infection-fighting white blood cells, to attack cancer cells. Sharma, a fellow MD Anderson oncology expert and clinician, says their work has received clinical approvals for treating Melanoma, kidney cancer, lung cancer, and bladder cancer. The scientists are now focused on expanding that treatment to other cancer types and building upon the established platform they've created, while also making sure nothing comes in the way of the facts of the science.

"It really requires that we dedicate ourselves to the basic science, understanding it and educating people about it, so we don't allow the facts and science get muddied by things that are political or nonfactual," Sharma says.

In a lot of ways, this is what Breakthrough has been able to do — communicate the facts on a platform where anyone can understand the science.

"We have a revolution on our hands, and thankfully we have people like Bill who can really tell the story well, because maybe as a scientist and a clinician, we're not always equally talented on telling the story to laypeople," Sharma says.

Moving forward, Allison says he's focused on finding out why the treatment fails in some instances, and he's determined to progress immunotherapy's success rate from the 20 to 40 percent rate he says he sees it at now to 100 percent.

"We've got all the basic tools, and we know what the main issues are," Allison says. "There's still a lot to do, but we need to be smart and do fact-based and mechanism-based combinations."

From pitch competitions to panels, here's how Houstonians will be representing at SXSW. Marie Ketring/via sxsw.org

10 can't-miss events at SXSW featuring Houston speakers

South by the Bayou

Plenty of Houstonians, SXSW badge in hand, will be headed to Austin to network, learn, and share the stage with the rest of the festivals attendees. While InnovationMap has highlighted a few of the faces to be on the lookout for this weekend, here's a roundup of 10 events that have a Houston speaker or participant.

3/8 — Featured Session: Opening Speaker, Brené Brown

SXSW is starting right out of the gate with a Houstonian. Brene Brown, a research professor at the University of Houston, will be the keynote address. Her thoughtful talk will focus on community and one's sense of belonging.

The SXSW keynote address will be at 11 am on Friday, March 8, at the Austin Convention Center. Learn more.

3/8 — Hysteria No More: Data, Doctors and Women’s Health

Gone are the days that medical professionals dismiss women's health concerns as "hysteria," but there's still room for improvement on the matter. Three ob/gyns will talk about new ways women are finding health care solutions outside the doctor's office.

Rashmi Kudesia, physician at CCRM Fertility Houston, is one of the panelists, which occurs on Friday, March 8, at the JW Marriott. Learn more.

3/8 — Equitable Growth Ecosystems for Entrepreneurs panel

The country has an equity problem — especially when it comes to startups and funding. Nationally, venture capital funds are not distributed in a way that represents the populations diversity, so how does the industry right the course?

Grace Rodriguez of Impact Hub Houston is among the panel that will discuss this at 3:30 pm on Friday, March 8, at the Hilton Austin Downtown. Learn more.

3/9 — Austinpreneur: The Texas Startup Manifesto

Texas is among the growing innovation ecosystems in the world, but there's plenty of untapped potential. This Capital Factory panel will focus on taking Texas to the next level.

Lawson Gow, founder and CEO of The Cannon, will be a panelist at the event, which begins at 11 am on Saturday, March 9, at the Hilton Austin Downtown. Learn more.

3/9 — Startup Funding: From Apprenticeships to Professions

Venture capitalism has changed tenfold since its start. Looking back on the history of early stage funding can help predict where it's going — from Silicon Valley to every corner of the world.

Station Houston CEO Gabriella Rowe is on the panel, which will take place at 12:30 pm on Saturday, March 9, at the Hilton Austin Downtown. Learn more.

3/9 — Making the Fight Against Cancer Even More Personal

No one loves discussing cancer, but there's a large group of scientists who have to daily and they develop new technologies and innovations to help discover a cure for the deadly affliction.

James Allison, researcher at the University of Texas MD Anderson Cancer Center and 2018 Nobel Prize recipient, will be on the panel discussing ways to innovate within cancer research. The program starts at 5 pm on Saturday, March 9, at the JW Marriott. Learn more.

3/10 — SXSW Pitch Presented by Cyndx Awards Ceremony

Two Houston startups are competing for an award in the 11th annual SXSW Pitch Event. Fluidity Technologies will be presenting as its drone controller, FT Aviator, in the Hyper-Connected Communities category on Saturday, March 9, at 5 pm, and Zibrio SmartScale, which is in the Health and Wearable category, will present on Sunday, March 10, at 5 pm.

The pitch awards will take place at 6:30 pm on Sunday, March 10, at the Hilton Austin Downtown. Learn more.

3/11 — Tech Diversity Report Card 2019

Is diversity and inclusion basically just a myth in technology? Is it something that's attainable at this point, and what can the industry do to make that happen? A group of panelists discuss based on their experience and observations.

Heidi Hoover, head of office at Houston-based Flanders Investment & Trade, will be a member of the panel, which occurs on Monday, March 11, at 5 pm, at Capital Factory. Learn more.

3/11 — Angel Investor Meetup

Calling all acting and aspiring investors — it's time to rally. Two Texas investors are gathering the troops to discuss trends and opportunities in the state's — and the world's — investment sector.

Samantha Lewis of Houston-based GOOSE Society of Texas will be one of the hosts of the meetup, which takes place on Monday, March 11, at 5 p.m, at the Fairmont Hotel. Learn more.

3/12 — AI & IoT Panel and Emerging Company Showcase

Houston-based Baker Botts and Global Corporate Venturing are setting the stage for emerging tech companies to shine. The event includes a panel, a showcase, and an evening of networking.

James McKell, of Chevron Technology Ventures, is representing Houston on the panel, which begins at 2 pm on Tuesday, March 12, at Hotel Van Zandt. Learn more.

Honorable mentions


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.